Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that adding imiquimod to diphenylcyclopropenone treatment significantly improves outcomes for alopecia areata patients who initially do not respond to diphenylcyclopropenone alone.

This study found that targeting androgen receptors with prostate cancer drugs ARN509 and finasteride induced remission and increased survival in a leukemia mouse model, suggesting a potential new treatment approach for acute myeloid leukemia.

This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.

This study found that intrathymic injection of recipient-type splenocytes into donor rats, combined with antilymphocyte antiserum, effectively prevented graft-versus-host disease for up to 300 days.

This case report describes two patients experiencing a bortezomib-induced skin eruption as multiple plaques on the trunk, with the lesions resolving spontaneously in about a week.

This review highlights valproic acid's efficacy and tolerability as a first-line treatment for various seizure types in both adults and children, emphasizing its minimal neurological adverse effects compared to other antiepileptic drugs.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

This study reports that a 15-year-old with trichotillomania showed improvement with aripiprazole treatment, though no consensus on treatment exists in the literature.

This study reported significant differences in adverse drug reactions among five chemotherapeutic regimens for oropharyngeal cancer, highlighting nausea/vomiting, alopecia, mucositis, myelosuppression, constitutional symptoms, and dermatological toxicities across different treatments.

In this randomized controlled trial, PRP combined with redensyl, saw palmetto, and biotin showed superior efficacy in improving androgenetic alopecia grading scores in male patients when compared to PRP with Procapil.

This study reports a novel method for synthesizing substituted hydantoins, including the anticonvulsant drug ethotoin, using safer reagents and fewer steps compared to conventional protocols.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

This review discusses the limited evidence on the efficacy of platelet-rich plasma for treating endocrine therapy-induced and permanent chemotherapy-induced alopecia and reports no new clinical results.

This review discusses arsenic trioxide therapy in acute promyelocytic leukemia and introduces a novel method using hair analysis to monitor arsenic exposure and correlate it with treatment timing, but reports no new clinical results.

This case report describes a child developing pancreatitis directly linked to valproic acid therapy.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

This study observed that upadacitinib demonstrated significant efficacy and favorable safety for treating alopecia areata over 12 months in a real-world setting, with patients having an atopic background showing better early response; no serious adverse events were reported.

This study found that using a pH-sensitive layered double hydroxide nanocarrier to deliver etoposide significantly reduced liver toxicity and enhanced the drug’s effectiveness in targeting and suppressing non-small cell lung cancer.

In this retrospective study from North France, apremilast was used in patients with psoriasis and recent cancer, showing a good safety profile and improved quality of life, though with 65.2% experiencing non-serious adverse events. The need for further research on oncological safety was highlighted.

Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.

This presentation explored recent developments in treating alcohol, opioid, and cannabis addiction, highlighting promising pharmacological and behavioral therapies, such as extended-release naltrexone for alcohol use and long-acting buprenorphine for opioids, alongside emerging strategies for cannabis use disorder.

This review discusses the choice and formulation of medicated and cosmetic shampoos for scalp disorders and hair aesthetics, providing guidelines based on hair types and patient age, and reports no new results.

This study reports that polyphenols from Annurca apples may safely promote hair growth and protect against chemotherapy-induced alopecia without interfering with chemotherapy regimens.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.

This study found that breast cancer patients treated with the docetaxel-doxorubicin regimen experienced various adverse drug reactions, with nausea being the most common and mainly mild in severity.

This study found that astaxanthin-loaded mucoadhesive patches effectively promoted recovery of oral premalignant lesions in vivo without the side effects seen with clinical tretinoin cream.

In this case report, researchers observed hair repigmentation in a man with metastatic renal cell carcinoma during treatment with axitinib, marking the first documented instance of this effect with axitinib without the use of hair dyes or other medications.